Follows adults with pulmonary arterial hypertension after an earlier study
Observes long-term treatment and outcomes in people who took part in TripleTRE.
Plain-language title generated from the registry record
Registry title: A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients
Key facts
- Where
- Berlin, Dresden, and Greifswald, GermanySee the 3 sites
Where in Germany
- DRK Kliniken Berlin WestendBerlin, GermanyNo longer taking part
- University Hospital Carl Gustav Carus of Technical University DresdenDresden, GermanyNo longer taking part
- Universitätsmedizin GreifswaldGreifswald, GermanyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AOP Orphan Pharmaceuticals AG
- Trial code
- NCT06445673
- Record updated
- 29 October 2026
- Original description
The goal of this observational study is to learn about the long-term development and outcomes of different treatment patterns of patients who initially participated in the TripleTRE study.Read full original descriptionShow less
A Prospective, Multicenter, International Non-interventional, Observational Cohort Study to Observe Long-term Treatment Patterns and Real-word Outcomes in PAH Group I Patients Previously Participating in TripleTRE - TripleTRE-NIS
The goal of this observational study is to learn about the long-term development and outcomes of different treatment patterns of patients who initially participated in the TripleTRE study.
The primary objective of this non-interventional follow-up study is to assess the long-term real-world clinical outcomes, including disease progression and survival rates, in patients who initially participated in and completed the randomized TripleTRE trial.
Planned observation duration per patient is a minimum of 3 years.
Inclusion: Patients previously participating in the randomized TripleTRE trial who are able and willing to provide a signed informed consent for study participation in NIS.
Exclusion: Patients who discontinued all medicinal PAH treatments (e.g. after successful lung transplantation); Patients who withdrew from the initial TripleTRE trial due to significant non-compliance with trial requirements (not adhering to therapy, not coming to hospital visits); Lost to follow-up patients of TripleTRE study.